Study of the efficacy and safety of tadalafil and imidafenacin combination therapy for benign prostatic hyperplasia with overactive bladder - Study of the efficacy and safety of tadalafil and imidafenacin combination therapy for benign prostatic hyperplasia with overactive bladder

Kawahara Clinic0 个研究点目标入组 30 人开始时间: 2016年4月19日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients who meet any of the following conditions at the first visit are excluded: (1) Residual urine volume of 100 mL or more (2) Suspicion of polyuria (3) Currently have, or have a past history of, urinary retention (4) Qmax of less than 5 mL/s (5) Neoplasm of the lower urinary tract such as prostate or bladder cancer, neurogenic bladder, urethral stricture, chronic bacterial prostatitis, urinary tract infection, urinary tract stone, or interstitial cystitis (6) Contraindication to the prescription of tadalafil or imidafenacin (7) Severe liver dysfunction, kidney dysfunction, or heart disease (8) Pyloric, duodenal, or other intestinal obstruction, decreased gastrointestinal motility or distention, paralytic ileus, closed angle glaucoma, or myasthenia gravis (9) Taking a prohibited concurrent medication within 4 weeks prior to starting the study (5&alpha-reductase inhibitor, sex hormone agent within 6 months) (10) Received a prohibited concurrent therapy within 8 weeks prior to starting the study (11) Change in dose or regimen within 8 weeks prior to starting the study of a concurrent restricted medication or therapy (12) Otherwise, determined to be inappropriate by the doctor

发起方

Kawahara Clinic